Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial.
about
Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.Gemtuzumab ozogamicin in acute myeloid leukemia.Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?Antigen-directed therapies: an effective tool in acute myeloid leukemia?Recent advances in the understanding and treatment of acute myeloid leukemia
P2860
Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Defining the dose of gemtuzuma ...... mg/m2 in the NCRI AML17 Trial.
@en
Defining the dose of gemtuzuma ...... mg/m2 in the NCRI AML17 Trial.
@nl
type
label
Defining the dose of gemtuzuma ...... mg/m2 in the NCRI AML17 Trial.
@en
Defining the dose of gemtuzuma ...... mg/m2 in the NCRI AML17 Trial.
@nl
prefLabel
Defining the dose of gemtuzuma ...... mg/m2 in the NCRI AML17 Trial.
@en
Defining the dose of gemtuzuma ...... mg/m2 in the NCRI AML17 Trial.
@nl
P2093
P2860
P1433
P1476
Defining the dose of gemtuzuma ...... mg/m2 in the NCRI AML17 Trial.
@en
P2093
Alan Burnett
Asim Khwaja
Gail Jones
Ian Thomas
Jamie Cavenagh
Jonathan Kell
Nigel Russell
Ove Juul Nielsen
Richard Clark
UK NCRI AML Study Group
P2860
P304
P356
10.3324/HAEMATOL.2016.141937
P577
2016-02-26T00:00:00Z